EUVIMEDOpdag EUVIMED
Crossref

Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study

Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Carlo A Vignoli, Giovanni Fiorillo, Francesco Piscazzi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Journal of Drugs in Dermatology · 2024-08-01 · 23 (8) · 632-639

DOI: 10.36849/jdd.7486 ↗

At a glance

Journal article in Journal of Drugs in Dermatology, published online on 2024-07-01. Written by Luigi Gargiulo and 9 co-authors. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Cited 7 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited. MATERIALS AND METHODS: We conducted a 104-week monocentric retrospective study on 102 psoriasis patients, all treated with guselkumab for at least 16 weeks. At each visit, we used the Psoriasis Area and Severity Index (PASI): effectiveness endpoints were the percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI compared with baseline. The Kaplan-Meier curve was used to assess the drug survival. RESULTS: At week 16, PASI 90 and PASI 100 were achieved by 49.02% and 32.35% of patients. At week 52, PASI 90 and PASI 100 were achieved by 71.58% and 55.79% of patients. After 2 years, PASI 90 and PASI 100 were achieved by 79.63% and 61.11% of patients. Obese and overweight patients had comparable PASI 90 and PASI 100 responses throughout the study. At week 104, no significant differences were observed between bio-naïve and bio-experienced patients regarding all effectiveness endpoints. No significant safety signals were reported in our study. After 24 months, 91.57% of our cohort was still on treatment with guselkumab. CONCLUSION: Our findings, although limited by the study's retrospective nature, confirm that guselkumab is a safe and effective therapeutic option for a "real-life" cohort of patients with psoriasis. J Drugs Dermatol. 2024;23(8):632-639. doi:10.36849/JDD.7486R1.

Subjects

MeSH terms (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedSeverity of Illness IndexHumansRetrospective StudiesMaleFemaleMiddle AgedTreatment OutcomeAdultAged

Substances

guselkumabAntibodies, Monoclonal, Humanized

Cite

APA

Gargiulo, L., Ibba, L., Cortese, A., Toso, F., Vignoli, C. A., Fiorillo, G., Piscazzi, F., Valenti, M., Costanzo, A., & Narcisi, A. (2024). Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology, 23(8), 632-639. https://doi.org/10.36849/jdd.7486

Vancouver

Gargiulo L, Ibba L, Cortese A, Toso F, Vignoli CA, Fiorillo G, et al. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology. 2024;23(8):632-639. doi:10.36849/jdd.7486

BibTeX
@article{Gargiulo2024,
  author = {Gargiulo, Luigi and Ibba, Luciano and Cortese, Andrea and Toso, Francesco and Vignoli, Carlo A and Fiorillo, Giovanni and Piscazzi, Francesco and Valenti, Mario and Costanzo, Antonio and Narcisi, Alessandra},
  title = {Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  volume = {23},
  number = {8},
  pages = {632--639},
  doi = {10.36849/jdd.7486}
}
Start for free →